Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin

Basha, Saleem; Hazenfeld, Staci; Brady, Rebecca C.; Subbramanian, Ramu A.

doi:10.1016/j.humimm.2011.03.001

Cited by 45 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of live attenuated influenza vaccines (LAIVs) is of interest since it results in viral protein synthesis in infected antigen-presenting cells which is a prerequisite for the efficient induction of virus-specific CTL responses [91–94]. LAIVs also induce antibody responses and, thus, have the capacity to induce both virus-specific CTL and B cells which both contribute to protective immunity.…”

Section: Live Attenuated Vaccinesmentioning

confidence: 99%

“…The use of these cold-adapted viruses results in mild infections of the upper respiratory tract only. It has been shown in humans that LAIVs induce stronger virus-specific T-cell responses than inactivated vaccines [94, 95]. Intranasal administration of H3N2 LAIV-afforded mice partial protection against infection with H1N1 virus.…”

Section: Live Attenuated Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Induction of Virus‐Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines

Hillaire

Osterhaus

Rimmelzwaan

2011

BioMed Research International

View full text Add to dashboard Cite

There is considerable interest in the development of broadly protective influenza vaccines because of the continuous emergence of antigenic drift variants of seasonal influenza viruses and the threat posed by the emergence of antigenically distinct pandemic influenza viruses. It has been recognized more than three decades ago that influenza A virus-specific cytotoxic T lymphocytes recognize epitopes located in the relatively conserved proteins like the nucleoprotein and that they cross-react with various subtypes of influenza A viruses. This implies that these CD8+ T lymphocytes may contribute to protective heterosubtypic immunity induced by antecedent influenza A virus infections. In the present paper, we review the evidence for the role of virus-specific CD8+ T lymphocytes in protective immunity against influenza virus infections and discuss vaccination strategies that aim at the induction of cross-reactive virus-specific T-cell responses.

show abstract

Section: Live Attenuated Vaccinesmentioning

confidence: 99%

Section: Live Attenuated Vaccinesmentioning

confidence: 99%

Induction of Virus‐Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines

Hillaire

Osterhaus

Rimmelzwaan

2011

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…LAIV is able to replicate its genome and its antigens in the cooler noses of vaccine recipients after intranasal administration, but the mutation prevents viral replication in warmer deep tissues, like the lung, thereby avoiding frank influenza virus infections (1). Unlike TIV, the ability of LAIV to infect cells, replicate, and amplify its antigens enables not only the induction of stronger antibody and CD4 + T cell responses, but also antiviral CD8 + T cell responses (14–16). Also, since LAIV is delivered intranasally by the same mucosal route used by natural influenza virus infection, the vaccine induces the production of secretory IgA (4, 5).…”

Section: Introductionmentioning

confidence: 99%

Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses

Crosby

Matchett

Anguiano-Zarate

et al. 2017

J Virol

View full text Add to dashboard Cite

Head-to-head comparisons of conventional influenza vaccines with adenovirus (Ad) gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against influenza virus infection in animal models. In most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors. In contrast, replication-competent Ad (RC-Ad) vaccines are markedly more potent but risk causing adenovirus diseases in vaccine recipients and health care workers. To harness antigen gene replication but avoid production of infectious virions, we developed “single-cycle” adenovirus (SC-Ad) vectors. Previous work demonstrated that SC-Ads amplify transgene expression 100-fold and produce markedly stronger and more persistent immune responses than RD-Ad vectors in Syrian hamsters and rhesus macaques. To test them as potential vaccines, we engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene from influenza A/PR/8/34 virus. We show here that it takes approximately 33 times less SC-Ad6 than RD-Ad6 to produce equal amounts of HA antigen in vitro. SC-Ad produced markedly higher HA binding and hemagglutination inhibition (HAI) titers than RD-Ad in Syrian hamsters. SC-Ad-vaccinated cotton rats had markedly lower influenza titers than RD-Ad-vaccinated animals after challenge with influenza A/PR/8/34 virus. These data suggest that SC-Ads may be more potent vaccine platforms than conventional RD-Ad vectors and may have utility as “needle-free” mucosal vaccines.IMPORTANCE Most adenovirus vaccines that are being tested are replication-defective adenoviruses (RD-Ads). This work describes testing newer single-cycle adenovirus (SC-Ad) vectors that replicate transgenes to amplify protein production and immune responses. We show that SC-Ads generate markedly more influenza virus hemagglutinin protein and require substantially less vector to generate the same immune responses as RD-Ad vectors. SC-Ads therefore hold promise to be more potent vectors and vaccines than current RD-Ad vectors.

show abstract

“…Cryopreservation of biological samples, when optimally performed, overcomes many of these challenges; we have previously demonstrated that cryopreserved T cells, of both CD4 and CD8 lineages, maintain full functionality in cytokine ELISPOT assays following thawing [1]. Strong evidence suggests cryopreservation is a reliable and convenient alternative to the use of fresh PBMC, resulting in its widespread use in both basic and clinical studies [2,3,4,5,6,7,8,9]. …”

Section: Introductionmentioning

confidence: 99%

Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in High-Throughput Human Immune Monitoring Studies

Ramachandran

Laux

Moldovan

et al. 2012

Cells

Self Cite

View full text Add to dashboard Cite

Cryopreserved peripheral blood mononuclear cells (PBMC) constitute an important component of immune monitoring studies as they allow for efficient batch- testing of samples as well as for the validation and extension of original studies in the future. In this study, we systematically test the permutations of PBMC thawing practices commonly employed in the field and identify conditions that are high and low risk for the viability of PBMC and their functionality in downstream ELISPOT assays. The study identifies the addition of ice-chilled washing media to thawed cells at the same temperature as being a high risk practice, as it yields significantly lower viability and functionality of recovered PBMC when compared to warming the cryovials to 37 °C and adding a warm washing medium. We found thawed PBMC in cryovials could be kept up to 30 minutes at 37 °C in the presence of DMSO before commencement of washing, which surprisingly identifies exposure to DMSO as a low risk step during the thawing process. This latter finding is of considerable practical relevance since it permits batch-thawing of PBMC in high-throughput immune monitoring environments.

show abstract

Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin

Cited by 45 publications

References 49 publications

Induction of Virus‐Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines

Induction of Virus‐Specific Cytotoxic T Lymphocytes as a Basis for the Development of Broadly Protective Influenza Vaccines

Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses

Optimal Thawing of Cryopreserved Peripheral Blood Mononuclear Cells for Use in High-Throughput Human Immune Monitoring Studies

Contact Info

Product

Resources

About